Biotransplant(BTRN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN)

BTRN 35.47

0.0%

Dec 9 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Pierre Borczuk who wrote (490)	1/26/2000 5:41:00 PM
From: scaram(o)uche	Read Replies (1) of 1475

Yeah, I saw that. For some offerings, a company commits to registering the shares for those who purchased them. It allows flexibility for the investors, in the event that they want to bail. Like I said, I am not a happy camper with respect to this last offering. I must, given my interest in the science, put that aside. I went to the presentation by Hockmeyer and Jim Young (Exec. V.P., R&D) at H&Q. Hockmeyer mentioned CD2 twice during his brief portion of the presentation, and Young used the word "intense" to describe clinical investigation for 507. They obviously need pipeline, and need it badly.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next